Instructions for use and dosage of tilpotide/tilsiparatide (Mufenda) for weight loss and hypoglycemia

Tirzepatide (Tirzepatide) is an innovative drug with both weight loss and hypoglycemic effects. It activates GLP-1 and GIP dual receptors at the same time, thereby enhancing insulin secretion, reducing appetite and improving metabolic status. In terms of specific usage and dosage, whether it is used to lower blood sugar or lose weight, it is administered as a subcutaneous injection once a week, and the principle of "start with a low dose and gradually increase the dose" must be followed to reduce the risk of gastrointestinal discomfort and improve tolerance.

For patients with type 2 diabetes, tisiparatide is usually started at 2.5 mg once a week for 4 weeks and then increased to 5 mg once a week. According to the patient's blood sugar control, it can be further increased step by step to 7.5mg, 10mg, 12.5mg or 15mg Once a week, and the interval between each dose increase is at least 4 weeks. The doctor will determine the maintenance dose based on the patient's fasting blood glucose, HbA1c changes and tolerance. Most patients can achieve significant hypoglycemic effects at 5–10mg, and higher doses can lead to more significant weight loss.

When used for weight management and weight loss, the dosage increase rhythm of tilsiparatide is similar to that of antidiabetic treatment, also starting from 2.5mg/ weeks. However, in order to obtain more lasting appetite suppression and fat loss, weight management people often use 10mg or 15mg once a week as the final maintenance dose. Dosage adjustments for weight loss purposes also need to be gradually increased in stages to reduce gastrointestinal side effects such as nausea, vomiting, and diarrhea. The injection site can be the abdomen, thigh, or upper arm, and the site needs to be rotated to avoid skin irritation.

Whether it is for weight loss or hypoglycemic treatment, it is not recommended to increase or decrease the dose of tisiparatide at will, let alone multiple injections or repeated use at short intervals. Patients need to keep the injection at a fixed time every week. If they forget, they can make up for it within 4 days (96 hours). If this time exceeds, they need to skip this injection and continue with the next one as originally planned. In addition, the risk of hypoglycemia (especially when insulin or sulfonylureas are used concomitantly), gastrointestinal effects, and changes in weight should be monitored while using this drug. Only through standardized, gradual and continuous treatment can tilsiparatide exert the best effect in reducing blood sugar and weight loss.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK585056/

xa0